The document this correction applies to
Timely disclosureWhat was corrected and how
A subsequent correction by the company to the contents of an already published filing.
FY2025 Full-Year Financial Results Presentation
Open the original document(1) The figures for “Operating CF” and “Investing CF” on page 22, “Cash Flows – Trends in Cash and Cash Equivalents at Fiscal Year-End”; (2) the FY2025 sale amount of cross-shareholdings on page 23, “Trends in Cross-Shareholdings”; (3) and (4) the FY2025 figure in the “Standalone Orders by Type” graph and the FY2024 figure in the “Standalone Orders by Purpose” graph in “Reference: Order Intake Plan Breakdown” on page 26; and (5) the research and development expense figures in “Reference: IR-Related Topics & Data” on page 41.
Operating CF +¥29,284 million / Investing CF −¥11,400 million / Research and development costs Consolidated FY2024 ¥2,971 million / FY2025 ¥3,282 million / Standalone FY2024 ¥2,747 million / FY2025 ¥3,036 million / FY2025 sale amount of cross-shareholdings Not disclosed / Standalone Orders by Type FY2025 Not disclosed / Standalone Orders by Purpose FY2024 Not disclosed
Operating CF +¥29,725 million / Investing CF −¥11,840 million / Research and development costs Consolidated FY2024 ¥2,971 million / FY2025 ¥3,931 million / Standalone FY2024 ¥2,747 million / FY2025 ¥3,684 million / FY2025 sale amount of cross-shareholdings Not disclosed / Standalone Orders by Type FY2025 Not disclosed / Standalone Orders by Purpose FY2024 Not disclosed
An error in the figures during the aggregation process was identified.
| Item | Details |
|---|---|
| Disclosure subject to correction | FY2025 Full-Year Financial Results Presentation |
| Original disclosure date | 12 May 2026 |
| Location of correction | (1) The figures for “Operating CF” and “Investing CF” on page 22, “Cash Flows – Trends in Cash and Cash Equivalents at Fiscal Year-End”; (2) the FY2025 sale amount of cross-shareholdings on page 23, “Trends in Cross-Shareholdings”; (3) and (4) the FY2025 figure in the “Standalone Orders by Type” graph and the FY2024 figure in the “Standalone Orders by Purpose” graph in “Reference: Order Intake Plan Breakdown” on page 26; and (5) the research and development expense figures in “Reference: IR-Related Topics & Data” on page 41. |
| Details of correction | Operating CF +¥29,284 million / Investing CF −¥11,400 million / Research and development costs Consolidated FY2024 ¥2,971 million / FY2025 ¥3,282 million / Standalone FY2024 ¥2,747 million / FY2025 ¥3,036 million / FY2025 sale amount of cross-shareholdings Not disclosed / Standalone Orders by Type FY2025 Not disclosed / Standalone Orders by Purpose FY2024 Not disclosed → Operating CF +¥29,725 million / Investing CF −¥11,840 million / Research and development costs Consolidated FY2024 ¥2,971 million / FY2025 ¥3,931 million / Standalone FY2024 ¥2,747 million / FY2025 ¥3,684 million / FY2025 sale amount of cross-shareholdings Not disclosed / Standalone Orders by Type FY2025 Not disclosed / Standalone Orders by Purpose FY2024 Not disclosed |
| Reason for correction | An error in the figures during the aggregation process was identified. |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.An error in the figures during the aggregation process was identified.